For serum C-reactive protein (CRP), whereas mean changes from baseline in Group A were similar with the two treatments (Additional file 1: Figure S6), for patients in Group B (i.e., those experiencing a moderate COPD exacerbation on entry), levels started to increase from Day 4 with placebo, but were unchanged with SNG001 (Fig. 7A). The gene discussed is CRP; the disease is chronic obstructive pulmonary disease.